Minimal residual disease assessment in chronic lymphocytic leukaemia

Best Practice & Research Clinical Haematology ◽

10.1016/j.beha.2007.03.004 ◽

2007 ◽

Vol 20 (3) ◽

pp. 499-512 ◽

Author(s):

Hazem A. Sayala ◽

Andy C. Rawstron ◽

Peter Hillmen

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Minimal Residual Disease ◽

Lymphocytic Leukaemia ◽

Residual Disease ◽

Disease Assessment ◽

Minimal Residual

Download Full-text

4.17 A Novel Approach to Minimal Residual Disease Assessment in Chronic Lymphocytic Leukaemia Utilizing the Tumour Specific Antigen CD160

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2011.09.137 ◽

2011 ◽

Vol 11 ◽

pp. S228-S229

Author(s):

Timothy Farren ◽

Fengting Liu ◽

Marion Macey ◽

Michael Jenner ◽

Archie Prentice ◽

...

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Minimal Residual Disease ◽

Lymphocytic Leukaemia ◽

Residual Disease ◽

Specific Antigen ◽

Disease Assessment ◽

Novel Approach ◽

Minimal Residual

Download Full-text

The assessment of minimal residual disease in chronic lymphocytic leukaemia: comparison of multi-colour flow cytometry and bone marrow trephine biopsy

Journal of Hematopathology ◽

10.1007/s12308-011-0133-5 ◽

2012 ◽

Vol 5 (4) ◽

pp. 305-309

Author(s):

E. Grey-Davies ◽

A. Attygalle ◽

A. Wotherspoon ◽

F. Carretero ◽

A. Morilla ◽

...

Keyword(s):

Bone Marrow ◽

Flow Cytometry ◽

Chronic Lymphocytic Leukaemia ◽

Minimal Residual Disease ◽

Lymphocytic Leukaemia ◽

Residual Disease ◽

Trephine Biopsy ◽

Bone Marrow Trephine ◽

Bone Marrow Trephine Biopsy ◽

Minimal Residual

Download Full-text

Eradication of Minimal Residual Disease (MRD) in Chronic Lymphocytic Leukaemia (CLL) with Alemtuzumab: a Phase II Study

http://isrctn.org/> ◽

10.1186/isrctn23153249 ◽

2012 ◽

Author(s):

Peter Hillmen

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Minimal Residual Disease ◽

Phase Ii ◽

Lymphocytic Leukaemia ◽

Residual Disease ◽

Phase Ii Study ◽

Minimal Residual

Download Full-text

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(21)00307-0 ◽

2021 ◽

Vol 8 (12) ◽

pp. e879-e890 ◽

Author(s):

Jacob D Soumerai ◽

Anthony R Mato ◽

Ahmet Dogan ◽

Venkatraman E Seshan ◽

Erel Joffe ◽

...

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Minimal Residual Disease ◽

Lymphocytic Leukaemia ◽

Residual Disease ◽

Phase 2 ◽

Small Lymphocytic Lymphoma ◽

Phase 2 Trial ◽

Minimal Residual

Download Full-text

Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia

10.1016/s0140-6736(14)60329-9 ◽

2014 ◽

Vol 383 ◽

pp. S66 ◽

Author(s):

Marwan Kwok ◽

Andy Rawstron ◽

Abraham Varghese ◽

Paul Evans ◽

Sheila O'Connor ◽

...

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Minimal Residual Disease ◽

Lymphocytic Leukaemia ◽

Residual Disease ◽

Prognostic Significance ◽

Disease Status ◽

Independent Prognostic Significance ◽

Minimal Residual

Download Full-text

Is chemoimmunotherapy maintenance of value in patients with chronic lymphocytic leukaemia and minimal residual disease?

The Lancet Haematology ◽

10.1016/s2352-3026(19)30107-3 ◽

2019 ◽

Vol 6 (9) ◽

pp. e441-e442

Author(s):

Anna M Fink

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Minimal Residual Disease ◽

Lymphocytic Leukaemia ◽

Residual Disease ◽

Minimal Residual

Download Full-text

Absence of Minimal Residual Disease Detectable by Facs, Southern Blot or PCR in Patients with Chronic Lymphocytic Leukaemia Treated with Fludarabine

Acta Oncologica ◽

10.3109/02841869409121773 ◽

1994 ◽

Vol 33 (6) ◽

pp. 627-630 ◽

Author(s):

Deborah S. Richardson ◽

Stephen A. Johnson ◽

John A. Hopkins ◽

Denise Howe ◽

Malcolm J. Phillips

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Southern Blot ◽

Minimal Residual Disease ◽

Lymphocytic Leukaemia ◽

Residual Disease ◽

Minimal Residual

Download Full-text

Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?

British Journal of Haematology ◽

10.1111/j.1365-2141.2006.06428.x ◽

2007 ◽

Vol 136 (3) ◽

pp. 379-392 ◽

Author(s):

Chadi Nabhan ◽

Steven Coutré ◽

Peter Hillmen

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Minimal Residual Disease ◽

Lymphocytic Leukaemia ◽

Residual Disease ◽

Minimal Residual

Download Full-text

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(19)30113-9 ◽

2019 ◽

Vol 6 (9) ◽

pp. e470-e479 ◽

Author(s):

Anne-Sophie Michallet ◽

Marie-Sarah Dilhuydy ◽

Fabien Subtil ◽

Valerie Rouille ◽

Beatrice Mahe ◽

...

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Minimal Residual Disease ◽

Induction Therapy ◽

Lymphocytic Leukaemia ◽

Residual Disease ◽

Phase 2 ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Minimal Residual

Download Full-text

Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation

British Journal of Haematology ◽

10.1111/bjh.14342 ◽

2016 ◽

Vol 176 (4) ◽

pp. 573-582 ◽

Author(s):

Abraham M. Varghese ◽

Dena R. Howard ◽

Christopher Pocock ◽

Andy C. Rawstron ◽

George Follows ◽

...

Keyword(s):

Chronic Lymphocytic Leukaemia ◽

Minimal Residual Disease ◽

Phase Ii ◽

Lymphocytic Leukaemia ◽

Phase Ii Trial ◽

Residual Disease ◽

Progression Free Survival ◽

Free Survival ◽

Minimal Residual

Download Full-text